R

Rodrigo Botero SAS | Medellin, Colombia

Research site

(Unclaimed)

Location

Carrera 65B No. 30-95 Conslutorio 213 Clinica Medellin Sede Occidente, Medellin, Antioquia, Colombia

Site insights

Top conditions

Top treatments

Pembrolizumab

Olaparib

MK-7339

Lenvatinib

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

2 of 3 total trials

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectab...

Enrolling

Advanced Solid Neoplasms

Drug: Olaparib

Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775])

This is a study of pembrolizumab (MK-3475, KEYTRUDA®) in combination with lenvatinib (E7080) versus treatment of physician's choice (doxorubicin or p...

Active, not recruiting

Endometrial Neoplasms

Drug: Pembrolizumab

Drug: Doxorubicin

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms